October 27, 2022
Dr. Joyce O’Shaughnessy closes the discussion with considerations for clinicians on monitoring patients with HER2-psotive breast cancer.
October 20, 2022
Advice for clinicians on how to discuss treatment and management strategies with patients with HER2-postitive breast cancer.
October 20, 2022
Discussion centered around the how the COVID-19 pandemic has influenced clinical treatment decisions across patients with HER2-positive breast cancer.
October 13, 2022
Dr. Joyce O’Shaughnessy briefly reviews and provides insights into the FeDeriCa and the PHranceSCa studies.
October 13, 2022
Clinical insights concerning the administration of combination pertuzumab/trastuzumab/hyaluronidase-zzxf for patients with HER2-positive breast cancer.
October 07, 2022
A breast cancer expert shares the current first-line standard of care for patients with HER2-positive breast cancer and presents scenarios where the standard treatment approach may not be appropriate.
October 07, 2022
Joyce O’Shaughnessy, MD shares an overview of the HER2-positive breast cancer landscape, focusing on prognosis and risk of recurrence for patients with early-stage and metastatic breast cancer.